- Research Areas
- Dynamic Brain Circuits and Connections in Health and Disease
- Core facilities
- Research administration services
- News & Events
- Brain Matters Newsletter
- Neuroscience Research Colloquia
You are hereNewsroom
Newly discovered gene function may reduce cell death in Alzheimer disease and Down syndrome
The discovery of a new role for a gene associated with neurodevelopmental and neurodegenerative disorders finds possible prenatal origin for Alzheimer disease (AD), according to a study published today in the journal Molecular Psychiatry. The protein, known as RCAN1, is commonly associated with Down syndrome as it overexpressed in Down syndrome during fetal brain development; the gene binds with messenger ribonucleic acid (mRNA) and has also been found elevated in post-mortem brain tissue from adults who had AD.
What is novel about the discovery is how an RNA aptamer—a compound that bonds amino acids—blocks gene expression and protects the cells, offering new insight into the role of RCAN1 and a possible future target for blocking RCAN1-related neurodegeneration.
RCAN1 is increased in people with Down syndrome and AD, and an imbalance of RCAN1 can trigger dangerous levels of inflammation resulting in damage to the mitochondria (the “batteries” of cells) and cell death in the cortex, the part of the brain responsible for speech and decision-making. More than 99 per cent of people with Down syndrome will develop AD later in life.
“Everyone carries RCAN1,” explains Dr. Weihong Song, who led the Canadian team in collaboration with Professor Xiulian Sun, a former Song lab PhD student, who now leads a lab of her own at the Qilu Hospital of Shandong University in China. “In balance, it maintains mitochondrial function; when dysregulated, it causes the mitochondria to swell and rupture leading to neuronal apoptosis, or cell death.”
This discovery further affirms Dr. Song’s hypothesis that AD may originate in the womb. In research published in 2017, Dr. Song and colleagues found that the chemical origins of AD may occur as a result of Vitamin A deficiency in the prenatal stages of brain development. While these new findings echo aspects of his earlier research, these new findings point to a specific interaction that may lead to a better understanding of AD disease pathogenesis.
“We don’t yet know why the RCAN1 gene is triggering Down’s syndrome and AD, but it leaves its epigenetic signature on the brain—we have found that RCAN1 increases amyloid-beta, which leaves deposits in the form of plaques in the brains of people with AD,” said Dr. Song. “We have more research to do, but it is encouraging to see that by blocking RCAN1 expression we may be able one day to alter its structure and prevent gene interactions that lead to neurodegeneration.”